「臨床研究証實，歐洲匈牙利政府核准對癌症病患具有高價值的天然營養食品」
維麥康AVEMAR經匈牙利政府正式核准以「癌症病患使用之醫療營養品」登記販售，成為匈牙利最多癌症病人使用的醫療輔助品，且外銷至歐洲、美國、亞洲多國。維麥康AVEMAR是唯一經過Phase III人體臨床實驗證實的癌症醫療營養輔助品；其製造與核准程序與抗癌藥物規格相同。臨床實驗證實：大腸癌患者在經歷手術與化學治療後，使用維麥康AVEMAR除了可使大腸癌的復發與轉移機率自42.3%降至16.7%外，更能提高患者的存活的機會，讓死亡率從31.7%降低至12.1%－降低約70%的死亡風險。此結果在2003年發表於全世界最具權威性的癌症期刊British Journal of Cancer上。
在台灣，大腸癌在第一期被發現時，治療後五年存活率可達90%，第二期為70%，若在第三期發現則只有35%的治癒機會，第四期更只有20%以下。手術、化學治療與放射線治療是癌症患者標準的治療方法，但極度的不適、身體各方面的衰弱與感官的失調，加上腫瘤加速消耗體內營養，讓治療時的副作用與危害也變成病人最擔心的問題之一，但使用維麥康AVEMAR將幫助大腸癌患者減緩化療的副作用，支持病患完成整個療程，詳細內容請看產品功效。
當然，維麥康AVEMAR最重要的作用是幫助病患減緩大腸癌惡化與捲土重來，因為不論是再度復發或是遠端轉移，都是癌症患者無法承受的，在治療後持續使用維麥康AVEMAR是每個癌症病患都必須做的事情。發表在2003年 British Journal of Cancer上的Phase III人體臨床試驗，在數個匈牙利的醫學中心合作進行，所有參加此研究的病患都接受傳統醫學治療，包括手術及化學或放射性治療；總共有176名大腸直腸癌病例，66名病患選擇在治療後持續服用維麥康AVEMAR，110名病患僅接受傳統醫學治療，兩組進行比較。
但試驗過程中有6名病人自行轉而服用維麥康AVEMAR而被從實驗統計中移除。兩組平均年齡皆約61歲，但選擇服用維麥康的病患原本的病情比較嚴重，有更多第四期的患者與更多已經發生轉移的案例，在服用維麥康AVEMAR七個月到三十一個月後，即使這66名病患原本的病況就比較不樂觀，服用維麥康AVEMAR後讓這些病患的死亡率降到12.1%，反而比原本病況較佳的110名病患的31.7%死亡率來的更低，服用維麥康AVEMAR降低了70%的死亡風險，再度發生復發或轉移的機率也由42.3%大幅下降至16.7%，而且沒有病患顯示任何不良反應。這樣的人體臨床試驗結果，讓我們必須將維麥康AVEMAR介紹給被大腸癌嚴重威脅的病患們，有效的實驗結果與完整的使用安全，讓治療後或治療中的患者們，能多做一些努力來捍衛自己的健康，有臨床實驗證實的維麥康AVEMAR一起幫助您長期對抗大腸癌。
| 飲用AVEMAR對腫瘤惡化相關事件發生率的影響 |
|
使用 (66 人次) |
未使用 (104 人次) |
| 數目 |
百分比 |
數目 |
百分比 |
| 新復發病例數 |
2 |
3.0 % |
18 |
17.3 % |
| 新轉移病例數 |
5 |
7.6 % |
24 |
23.1 % |
| 死亡病例數 |
8 |
12.1 % |
33 |
31.7 % |
| 腫瘤惡化整體病例數 |
11 |
16.7 % |
44 |
42.3 % |
The crude incidence of colorectal cancer (CRC) in the European Union is 53 cases/100,000 per year, with a mortality rate of 30/100,000 per year. In 2001, 2594 Hungarian men and 2258 women died from CRC, twice as many as 25 years earlier. The figures are also double that of current EU mortality rates. In Taiwan, more people died of malignant tumors than any other disease and CRC is the third most deadly cancer. According to the statistics of 2001, the crude incidence of CRC is 32.9 cases/ 100,000 and the mortality rate is 15.5 cases/ 100,000. CRC accounts for approximately 12-13 % of all cancers and around 50 % of newly diagnosed CRC patients will eventually progress due to micro-metastases (and possibly macro-metastases) and die of their disease. As a result, effective systemic treatment is an important and integral part of the management strategy for CRC. Curative surgery means, in addition to that of the localized primary tumor, the removal of solitary or localized multifocal metastases in the liver and lung, if possible. Removal of regional lymph nodes (a minimum of 12 nodes is required for pathological staging) is an integral part of radical surgery. Preoperative radiotherapy may effectively decrease the local recurrence rate.
5 FU-based chemotherapy is the backbone of postoperative therapy recommended for patients with pT3 and pT4 (Dukes' B2 and B3) tumors and for patients with nodal involvement (N1-2, i.e., Dukes' C1-3) when there has been no preoperative radiotherapy. Frequently used schedules include 5 FU 425mg/m2 + Leucovorin 20 mg/m2 five days a week for four weeks. Combination with irinotecan or oxaliplatin may enhance the efficacy of 5 FU-based therapy.
As the limitations of the efficacy of systemic therapy for this condition are well known, every opportunity needs to be taken to improve it. Experimental data, the product's known selective anti-tumor activity and multiple effect mechanisms, and preliminary clinical results all support the expectation that Avemar, used as a supportive agent in CRC treatment, has beneficial effects.
A prospective cohort study was conducted on 170 UICC-TNM stage I-IV patients who had undergone radical surgery. 66 were given Avemar as a complementary therapy alongside standard treatment, while the remaining 104 patients received only standard therapy and served as a control group. The proportion of progression-related events within the groups was as follows: Avemar vs. control: local recurrence: 3% vs.17.3%; new metastases: 7.6% vs. 23.1%; death: 12.1% vs. 31.7% (p<0.01).
The cumulative number of patients with progression was 16.7% vs. 42.3% (p<0.001). The overall and progression-free survival time (p=0.0278 and p=0.0184 respectively) was longer in the Avemar group. It is indicated that supportive treatment resulted in an unquestionable increase in anticancer efficacy. The results of supportive Avemar therapy, as well as knowledge of the many facets of its effect mechanism, make the clinical study of colorectal cancer particularly important. The significance of these results is increased when one takes into consideration the fact that the prognosis for the Avemar group was worse than that for the control group. Supportive treatment with Avemar has the potential to contribute to the improvement of global prognosis in a disease with high incidence and whose current systemic therapy has limited efficacy.
TOP
Cumulative overal survival probability curves of colorectal cancer patients (Kaplan-Meier estimation)
Cumulative progression-free survival probability curves of colorectal cancer patients (Kaplan-Meier estimation)
TOP
Occurance of progression-related events (end-point analysis)
| |
Avemar (n=66) |
Control (n=144) |
| NO |
% |
NO |
% |
Patients with new
recurrent diseasea |
2 |
3.0 |
18 |
17.3 |
Patients with new
metastatic lesionsa |
5 |
7.6 |
24 |
23.1 |
| Deathsa |
8 |
12.1 |
33 |
31.7 |
Overall patients
with progression
eventsb |
11 |
16.7 |
44 |
42.3 |
|
ap,0.01; bp,0.001
(Jakab et al., 2003)
